Literature DB >> 6652966

Inhibition of complement-mediated solubilization of antigen-antibody complexes by sera from patients with rheumatoid arthritis.

J K Naama, W S Mitchell, K Whaley.   

Abstract

Sera and synovial fluids from patients with seropositive rheumatoid arthritis inhibit the ability of normal serum to prevent immune precipitation. Sera from patients with seronegative forms of arthritis contain little inhibitory activity. Studies of the mechanism of action of the inhibitor show that it reduces C4 consumption by antigen-antibody complexes. These findings suggest that the binding of C1 to complexes or activation of C1 is impaired. The possibility that the inhibitory activity may be mediated by rheumatoid factor is discussed. As inhibitory activity is more prevalent and of a higher level in patients with extra-articular features, it is possible that it may play a pathogenetic role.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652966      PMCID: PMC1535903     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

4.  A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement.

Authors:  T A Gaither; D W Alling; M M Frank
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

5.  Complement-mediated inhibition of immune precipitation. II. Analysis by sucrose density gradient ultracentrifugation.

Authors:  J A Schifferli; D K Peters
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

6.  Amino acid sequence around the thiol and reactive acyl groups of human complement component C4.

Authors:  R D Campbell; J Gagnon; R R Porter
Journal:  Biochem J       Date:  1981-11-01       Impact factor: 3.857

7.  Complement-mediated inhibition of immune precipitation in patients with immune complex diseases.

Authors:  J K Naama; W S Mitchell; A Zoma; J Veitch; K Whaley
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

8.  Inhibition of immune precipitation by complement.

Authors:  J A Schifferli; S R Bartolotti; D K Peters
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

9.  Evidence for presence of an internal thiolester bond in third component of human complement.

Authors:  B F Tack; R A Harrison; J Janatova; M L Thomas; J W Prahl
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

10.  Complement fixation by a two-component antibody system: immunoglobulin G and immunoglobulin M anti-globulin (rheumatoid factor). Parodoxical effect related to immunoglobulin G concentration.

Authors:  F R Schmid; I M Roitt; M J Rocha
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  12 in total

1.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; J Veitch; K Whaley
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

2.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

3.  An inhibitor of complement-mediated prevention of immune precipitation in rheumatoid arthritis--relationship to disease activity and systemic manifestations.

Authors:  W S Mitchell; J Veitch; J Hunter; A Zoma; H Capell; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

4.  Inhibition of C1q binding to antigen-antibody complexes by a factor in rheumatoid arthritis serum.

Authors:  I P Niven; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

5.  Complement-mediated inhibition of immune precipitation in rheumatoid vasculitis.

Authors:  M M O'Sullivan; N Amos; A Bedwell; B D Williams
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

6.  Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor.

Authors:  M M O'Sullivan; N Amos; B D Williams
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

7.  Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.

Authors:  G Doekes; J Schouten; A Cats; M R Daha
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

8.  IgM-RF prevents complement-mediated inhibition of immune precipitation.

Authors:  W S Mitchell; J K Naama; J Veitch; K Whaley
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

9.  A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

Authors:  F B Waldo; J Forristal; L Beischel; C D West
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

10.  Circulating immune complexes associated with decreased complement-mediated inhibition of immune precipitation in sera from patients with bacterial endocarditis.

Authors:  M A Kerr; E Wilton; J K Naama; K Whaley
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.